Drug Profile
GSK 1995057
Alternative Names: GSK1995057Latest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Antibodies
- Mechanism of Action Type 1 tumour necrosis factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute lung injury; Adult respiratory distress syndrome
Most Recent Events
- 30 Sep 2012 GlaxoSmithKline completes a phase I trial in Healthy volunteers in United Kingdom (NCT01587807)
- 30 Apr 2012 GlaxoSmithKline completes a phase I trial in Healthy volunteers in United Kingdom (NCT01476046)
- 31 Mar 2012 Phase-I clinical trials in Acute lung injury in United Kingdom (Inhalation)